New Pharma will crowd out Big Pharma
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Aimee Donnellan
LONDON, June 11 (Reuters Breakingviews) -Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N, $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O. As drugmakers wrestle with the need to constantly replenish their stocks of remedies via deals, big names may struggle to remain relevant.
Big Pharma companies have taken over a century to become market leaders. Swiss giant Roche was founded in 1896, while U.S. drugmaker Pfizer has been around since 1849, when typhoid and scarlet fever were among the biggest killers. Both giants came to dominate the industry by making savvy calls on common diseases, like cancer and infectious ailments. M&A is also a critical part of their growth story – witness Roche’s $47 billion takeover of Genentech in 2009, and Pfizer’s $43 billion purchase of cancer specialist Seagen in 2023.
But now a new breed of tech-savvy drugmakers, once the obvious prey of their established rivals, are threatening their dominance. Over the past five years, Amgen AMGN.O, Regeneron REGN.O, Genmab GMAB.CO and Vertex have added $270 billion to their combined market values. That compares to Big Pharma firms like Pfizer, Novartis, GSK GSK.L, Sanofi SASY.PA and Roche, whose aggregate market value has declined by nearly $80 billion in the same period.
The growth of the once bite-sized drugmakers is already creating a hotter climate for takeovers. Last year, the value of biopharma M&A increased by 79% to $152 billion. In 2022, $164 billion Amgen, which is now roughly the same size as Pfizer after increasing fivefold since 2010, splurged $28 billion on Horizon Therapeutics. Analysts reckon Horizon had been on a list of deal targets for more established players for some time.
This increased competition comes at a particularly inopportune moment for executives from traditional drugmakers like Pfizer, Merck MRK.N and GSK, all of which will gradually lose patent exclusivity on some of their top-selling drugs. Merck’s patent on its cancer drug Keytruda, which delivered over $25 billion in sales in 2023, expires in four years. The United States’ Inflation Reduction Act also gives biologic drugs, which are created by using living cells and were historically made by smaller technology-driven drugmakers, longer patents than more established drugs like insulin and antihistamines. That puts an even greater value on the companies that make those newer products.
Deals are often the quickest way of replenishing a drug cupboard. But if there is increased competition, the price of smaller drugmakers will spike. AbbVie’s ABBV.N $10 billion purchase of ImmunoGen earlier this year included an eye-watering 95% premium, suggesting the trend is already in full swing. There are also fewer obvious targets to choose from. In 2022 new drug approvals in the U.S. were down by a quarter, to the lowest level since 2016. Eventually, today’s Big Pharma and their biotech challengers may swap places.
Follow @aimeedonnellan on X
Graphic: Tech-driven drugmakers’ market values are closing in on Big Pharma https://reut.rs/3x2Hy3x
Editing by George Hay and Oliver Taslic
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
